

IMSUT Hospital

Department of Pharmacy

薬剤部

| | |
|------------|---------------------------|
| Director | Seiichiro Kuroda |
| Chief | Yohei Iimura |
| Chief | Sonoe Minegishi-Higashino |
| Pharmacist | Masaaki Ishibashi |
| Pharmacist | Mika Yamamura-Noguchi |
| Pharmacist | Mai Yokota |

| | | |
|------|----|-----|
| 薬剤部長 | 黒田 | 誠一郎 |
| 薬剤主任 | 飯村 | 洋平 |
| 薬剤主任 | 峰岸 | 園恵 |
| 薬剤師 | 石橋 | 正祥 |
| 薬剤師 | 山村 | 実佳 |
| 薬剤師 | 横田 | 舞 |

The Department of Pharmacy seeks to provide high-quality pharmaceutical care services. We contribute to the team approach to patient-oriented medical care and provides a drug distribution service. We are also trying to contribute to propel the right use of medicines for patients.

<Publication>


1. Kuroda Seiichiro ,Kiyomi A, Imai S, Sugiura.M. :Japanese Journal of Infection Prevention and Control 2023; 38(3): 114-122.
2. Kuroda Seiichiro, Okuno.M, Kiyomi A, Imai S, Sugiura M. :Japanese Journal of Infection Prevention and Control 2024; 39 (4): 126-132.

<Clinical Trial>

- Clinical trial for cancer supportive care led by pharmacist
We are working on phase III study regarding to prevention of capecitabine-induced hand-foot syndrome (HFS). This project is supported by a Practical Research for Innovative Cancer Control project grant (No. 24ck0106978h0001 J-SUPPORT2401/JORTC-SUP06 (J-DIRECT): a randomized, double blind, placebo-controlled Phase III study evaluating preventive effect of diclofenac cream for capecitabine related hand foot syndrome) from the Japan Agency for Medical Research (AMED). Primary investigator is Yohei Iimura. This trial is based on our phase II study (T-CRACC study, BMC Gastroenterol. 2022;22:341.). New evidence will be published in 2025 from our pharmacy.
- Collaboration with MASCC
Yohei Iimura is the member of Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group. Skin toxicity guideline project is ongoing. MASCC guideline regarding to EGFR-I related skin toxicity and hand-foot syndrome and nail toxicity guideline will be published in 2025.
- Skin toxicity guideline project with JASCC
Yohei Iimura is the board member of Japanese Association of Supportive Care in Cancer (JASCC) Oncodermatology Study Group. Skin toxicity guideline project for Asian countries is ongoing. Several review regarding to skin

Mechanism of developing HFS


- (i) Inhibition of the proliferation of skin basal cells
- (ii) Secretion of drugs from the eccrine sweat glands
- (iii) Involvement of drug degradation products
- (iv) An inflammatory response caused by IL-1a, IL-1b, IL-6, and reactive oxygen species



Chem Res Toxicol. 2016;29:1591-1601.
 Oncology (Williston Park). 2000;14:19-23
 J Dtsch Dermatol Ges. 2010;8:602-61
 Hum Cell. 2013;26:8-18.



Preventive Effect of Diclofenac Topical for Capecitabine Related Hand Foot Syndrome a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial: J-SUPPORT2401/JORTC-SUP06



toxicity for Asia will be published in 2025.

● Observational study

Two following prospective observational study are ongoing.

- Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team for gastrointestinal cancer chemotherapy: prospective observational study; M-CAST study (BMC

Gastroenterol. 2023;23:215.)

-A prospective observational study to evaluate the efficacy of fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in patients receiving platinum- based chemotherapy (LODEC-N) (J Clin Trials. 13:532.)

We can establish new evidence with high quality clinical studies in various region.